Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

RNF5 loss decreases ERK and Akt activation, CDK1 and Smo expression and KSHV lytic replication in PEL cells. by Xiaojuan Li (351842)

Decreased expression levels of the MYO6 protein in <i>ksv</i> mice. by Yuta Seki (4385833)

“…Expression of MYO6 is completely ablated in the hair cells of <i>Myo6</i>^-/- mice (C). Scale bar = 5 μm. D and E. Western blot analysis of homogenates prepared from the inner ears of +/+, +/<i>ksv</i> and <i>ksv/ksv</i> mice at P30 detected with anti-MYO6 (N-ter, D) and MYO6 (C-ter, E) antibodies (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0183477#pone.0183477.s007" target="_blank">S2 Table</a>). …”

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Significantly decreased adhesion to host cells by the Δ<i>tad123</i> mutant (A) and time-dependent recovery (B). by Tra-My Duong-Nu (7300970)

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Subjects:

Increasing the stimulus intensity, i.e. the number of spikes in a volley, decreases axonal transmission times and the latency of stimulus response. by Helmut Schmidt (248902)

Data_Sheet_5_Chemical Similarity of Co-occurring Trees Decreases With Precipitation and Temperature in North American Forests.CSV by Brian E. Sedio (10875330)

“…Variation in metabolite richness among communities was positively correlated with species richness, but variation in mean chemical similarity was not. Our results are consistent with the hypothesis that plant metabolomes play a more important role in community assembly in wetter and warmer climates, even at temperate latitudes, and suggest that metabolomic traits can provide unique insight to studies of trait-based community assembly.…”

Decreased Tbx2 expression in the AV myocardium of <i>Ezh2</i> mutant mice. by Li Chen (5749)